Provided by Tiger Fintech (Singapore) Pte. Ltd.

Elevation Oncology, Inc.

0.3500
+0.00992.91%
Post-market: 0.3400-0.0100-2.86%17:41 EDT
Volume:586.11K
Turnover:203.34K
Market Cap:20.73M
PE:-0.45
High:0.3557
Open:0.3436
Low:0.3387
Close:0.3401
Loading ...

Company Profile

Company Name:
Elevation Oncology, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
34
Office Location:
101 Federal Street,Suite 1900,Boston,Massachusetts,United States
Zip Code:
02110
Fax:
- -
Introduction:
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

Directors

Name
Position
Shawn Leland
President, Chief Executive Officer and Director
Steven A. Elms
Chairman of the Board, Director
Colin Walsh
Director
Lori Hu
Director
R. Michael Carruthers
Director
Richard S. Gaster
Director
Timothy Clackson
Director

Shareholders

Name
Position
Shawn Leland
President, Chief Executive Officer and Director
Joseph J. Ferra, Jr.
Chief Financial Officer